Can Baseline PSA Measured in Middle Age Be Used for Early Prostate Cancer Detection?

The Debate About Early Prostate Cancer Detection with PSA
One of the most debated cancer screening issues is the role of Prostate Specific Antigen(PSA) in prostate screening. Indolent, slow and benign-progressing prostate cancers are increasingly diagnosed and treated unnecessarily, called overdiagnosis (see “Is Gleason 6 prostate cancer, and should it be treated?”). Studies worldwide seek optimal strategies. Dr. Evan Kovac and colleagues at Montefiore Medical Center, New York, added a secondary analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, conducted between 1993 and 2000 (PLCO), a prospective cohort study. Their analysis was published on 15 January 2020 in JAMA Network Open . Sponsored by the US National Cancer Institute, PLCO included people aged 55-74, approximately 148,000 participants. Followed until 2015, they provided valuable screening and cancer mortality data.
Study Details
- Dr. Kovac's team analyzed men aged 55 to 60, totaling 10,968 participants.
- Median follow-up was 11.7 years.
- They statistically examined the association between baseline PSA and rates of clinically significant prostate cancer.
- Dr. Kovac and colleagues found that baseline total PSA levels of 2 ng/mL or less were associated with much lower clinically significant prostate cancer risk.
- Risk was lowest below baseline PSA 0,49 ng/mL.
Clinically Significant Prostate Cancer Incidence by Subgroup:
- baseline PSA ≤ 0,49 ng/mL: %0,4;
- baseline PSA 0,50-0,99 ng/mL: % 1,5;
- baseline PSA 1,00-1,99 ng/mL: %5,4;
- baseline PSA 2,00-2,99 ng/mL: %10,6;
- baseline PSA 3,00-3,99 ng/mL: %15,3;
- ≥ 4,00 ng/mL: %29,5.
In Conclusion, among men aged 55 to 60, PSA predicted long-term clinically significant prostate cancer. Dr. Kovac and colleagues suggested less frequent screening below 2 ng/mL and possibly discontinuing screening below 1 ng/mL in this age range.
Note: Researchers defined clinically significant prostate cancer using clinical or pathological criteria: Gleason 7 or higher, clinical stage cT2b or higher, pathological stage pT3 or higher, and prostate cancer death.
US Actor Ben Stiller's Story, Which Intensified the PSA Debate

A story intensifying PSA debates became prominent in social media, oncology, and Hollywood in 2016. World-famous comedian Ben Stiller was diagnosed at 48. He compares learning he had cancer to the moment the lead character of Breaking Bad , Walter White, discovers lung cancer, but notes no camera filmed him and his doctor. After learning he had prostate cancer, the first thing he didwas Google who had survived it. Seeing that Robert de Niro, former US Secretary of State John Kerry, and others had prostate cancer and lived for years reassured him. His diagnostic story began in 2012, when his doctor recommended PSA testing. He had no symptoms suggesting prostate cancer, no high-risk factors, and no family history. Because baseline PSA exceeded normal, Ben Stiller underwent repeat measurements for 1.5 years. Continued increases prompted referral to a urologist, who performed a digital rectal examination (rectal palpation) and then ordered MR imaging, followed by prostate biopsy . Pathology showed moderately aggressive prostate cancer. Within 3 months he underwent robot-assisted laparoscopic (minimally invasive) radical prostatectomy . Now 54, he continues living healthily. Ben Stiller, emphasizing that his approach is not scientific , recommends more men obtain baseline PSA monitoring. He is glad he tested earlier than American Cancer Society recommendations and says screening may have saved his life.
- You May Be Interested: Celebrities and Their Cancers
Conclusion
The study and Ben Stiller's story support PSA blood testing for prostate screening earlier than currently recommended, for example at 45-50. However, testing all men early risks excessive testing, biopsies, and intervention for mild cancers that may never cause symptoms, such as Gleason score 6. We therefore recommend: men with at least 10 years' life expectancy, aged 50 or older, should have the opportunity for informed discussion with professionals about benefits, risks, and uncertainties before deciding on screening. Prostate cancer screening should not occur without an informed decision-consent process.
Sources
Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
JAMA Netw Open. 15 Jan 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.